Pluri Inc
Company Profile
Business description
Pluri Inc is a biotechnology company engaged in the research, development, and manufacturing of cell-based products, as well as the commercialization of cell therapeutics and related technologies aimed at delivering solutions across a range of industries, including regenerative medicine, immunotherapy, food tech, CDMO, and AgTech. The company uses its 3D cell expansion technology platform to develop placenta-based cell therapy product candidates (PLX-PAD and PLX-R18) for the treatment of inflammatory, muscle injuries, and hematologic conditions. In addition, it offers CDMO services through PluriCDMO, has launched a novel immunotherapy platform, and is engaged in developing cultivated, cell-cultured coffee and meat.
Contact
MATAM Advanced Technology Park
Building No. 5
Haifa3508409
ISRT: +972 747108600
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2026
Employees
142
Stocks News & Analysis
stocks
Earnings losers: TWE, GMG, SUN and more fall on weaker profits
stocks
ASX healthcare leader still undervalued after rally
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,251.50 | 83.10 | -0.89% |
| CAC 40 | 8,523.14 | 124.36 | 1.48% |
| DAX 40 | 25,150.93 | 109.76 | -0.43% |
| Dow JONES (US) | 49,588.98 | 193.82 | 0.39% |
| FTSE 100 | 10,707.27 | 20.38 | 0.19% |
| HKSE | 27,081.91 | 668.56 | 2.53% |
| NASDAQ | 22,886.07 | 203.34 | 0.90% |
| Nikkei 225 | 56,825.70 | 642.13 | -1.12% |
| NZX 50 Index | 13,420.43 | 111.91 | 0.84% |
| S&P 500 | 6,905.36 | 4.15 | -0.06% |
| S&P/ASX 200 | 9,026.00 | 84.10 | -0.92% |
| SSE Composite Index | 4,082.07 | 51.95 | -1.26% |